brexpiprazole vs quetiapine
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of brexpiprazole and quetiapine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Rexulti
Seroquel
Rexulti is a medication used to treat certain mental health conditions. It can help with depression, schizophrenia, and agitation related to Alzheimer's disease.
Quetiapine is a medicine that belongs to a class of drugs called atypical antipsychotics. It is used to treat mental disorders like schizophrenia and bipolar disorder.
Rexulti can be used with antidepressants to treat major depressive disorder in adults. It can also treat schizophrenia in adults and children 13 years and older. Additionally, Rexulti can help manage agitation in people with dementia due to Alzheimer's disease. Rexulti should not be used as needed for agitation related to dementia.
Quetiapine is used to treat schizophrenia in adults and teens (13-17 years old). It also treats manic and depressive episodes of bipolar disorder in adults and children (10-17 years old). For bipolar disorder, it can be used alone or with other medicines like lithium or divalproex.
Rexulti affects the balance of certain natural chemicals in the brain. These chemicals, called neurotransmitters, include dopamine and serotonin. By affecting these chemicals, Rexulti can help improve mood, thinking, and behavior.
Quetiapine works by changing the levels of certain natural substances in the brain. These substances are called neurotransmitters. By affecting these neurotransmitters, quetiapine can help reduce symptoms of mental disorders.
- • Weight gain
- • Feeling sleepy
- • Restlessness or feeling like you need to move
- • Feeling sleepy
- • Dry mouth
- • Dizziness
- • Constipation
- • Feeling weak
- Weight Increased 1,673
- Akathisia 854
- Tremor 630
- Anxiety 591
- Tardive Dyskinesia 590
- Toxicity To Various Agents 9,720
- Insomnia 9,103
- Fatigue 8,863
- Diabetes Mellitus 8,342
- Weight Increased 8,154
Elderly patients with dementia-related psychosis who are treated with antipsychotic drugs have an increased risk of death. Rexulti is not approved to treat dementia-related psychosis unless it is related to agitation from Alzheimer's disease. Antidepressants may increase the risk of suicidal thoughts and behaviors in young adults and children. Tell your doctor right away if you have thoughts of harming yourself.
Quetiapine may increase the risk of death in elderly patients who have psychosis related to dementia. Quetiapine can also increase the risk of suicidal thoughts and behavior in children, teens, and young adults. Watch for worsening symptoms or suicidal thoughts, and tell your doctor right away.
Tell your doctor if you are pregnant or plan to become pregnant. Babies born to mothers who take Rexulti in the last 3 months of pregnancy may have withdrawal symptoms or other problems after birth. There is a pregnancy registry to monitor outcomes in women exposed to Rexulti during pregnancy. You can contact the registry at 1-866-961-2388.
If you take quetiapine during the last 3 months of pregnancy, your baby may have withdrawal symptoms or other problems after birth. There is a pregnancy registry to track outcomes in women who take quetiapine during pregnancy. Talk to your doctor if you are pregnant or plan to become pregnant.
Also Compare, Nearby Drugs
Compare brexpiprazole with
Compare quetiapine with
How to Read This brexpiprazole vs quetiapine Comparison
brexpiprazole is classified in the Atypical Antipsychotic drug class, while quetiapine sits within the Atypical Antipsychotic class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, brexpiprazole has 4,338 submissions while quetiapine has 44,182. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for brexpiprazole or quetiapine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.